UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 322

Sortiert nach

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Expert opinion on drug metabolism & toxicology, 2020-11, Vol.16 (11), p.1063-1078

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Frontiers in immunology, 2020-12, Vol.11, p.599417-599417

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Journal of psychopharmacology (Oxford), 2020-03, Vol.34 (3), p.326-335

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Clinical and translational science, 2021-11, Vol.14 (6), p.2132-2138

2021

Link zum Volltext

Verfügbarkeit prüfen

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Current drug metabolism, 2021-01, Vol.22 (5), p.399

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Drugs in R&D, 2024-03, Vol.24 (1), p.97-108

2024

Link zum Volltext

Verfügbarkeit prüfen

Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects

Biomedicine & pharmacotherapy, 2021-01, Vol.133, p.110955, Article 110955

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Scientific reports, 2022-11, Vol.12 (1), p.19067-7, Article 19067

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects

European journal of clinical pharmacology, 2020-03, Vol.76 (3), p.431-437

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Journal of dermatological science, 2018-02, Vol.89 (2), p.136-145

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm

Frontiers in pharmacology, 2021-02, Vol.11, p.628956

2021

Link zum Volltext

Verfügbarkeit prüfen

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

European journal of clinical pharmacology, 2008-01, Vol.64 (1), p.43-50

2008

Link zum Volltext

Verfügbarkeit prüfen

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

International journal of molecular sciences, 2019-07, Vol.20 (13), p.3232

2019

Link zum Volltext

Verfügbarkeit prüfen

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

Journal of pharmacokinetics and pharmacodynamics, 2021-04, Vol.48 (2), p.213-224

2021

Link zum Volltext

Verfügbarkeit prüfen

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

European journal of clinical pharmacology, 2017-02, Vol.73 (2), p.151-156

2017

Link zum Volltext

Verfügbarkeit prüfen

Integrated pharmacokinetics and pharmacodynamics in drug development

Clinical pharmacokinetics, 2007-01, Vol.46 (9), p.713-737

2007

Link zum Volltext

Verfügbarkeit prüfen

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Scientific reports, 2020-03, Vol.10 (1), p.4410, Article 4410

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

CPT: pharmacometrics and systems pharmacology, 2021-07, Vol.10 (7), p.735-747

2021

Link zum Volltext

Verfügbarkeit prüfen

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Nature medicine, 2007-02, Vol.13 (2), p.150-155

2007

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

CPT: pharmacometrics and systems pharmacology, 2023-01, Vol.12 (1), p.74-86

2023

Link zum Volltext

Verfügbarkeit prüfen

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

Clinical pharmacokinetics, 2017-12, Vol.56 (12), p.1499-1511

2017

Link zum Volltext

Verfügbarkeit prüfen

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Pharmacology, 2014-01, Vol.94 (3-4), p.148-156

2014

Link zum Volltext

Verfügbarkeit prüfen

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

Clinical therapeutics, 2016-05, Vol.38 (5), p.1228-1236.e1

2016

Link zum Volltext

Verfügbarkeit prüfen

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

Clinical pharmacokinetics, 2013-08, Vol.52 (8), p.685-692

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

Journal of clinical pharmacology, 2013-11, Vol.53 (11), p.1131-1138

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(254)

Publikationsform

Artikel
(319)
Tagungsberichte
(3)

Sprache

Englisch
(322)
Japanisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

Integrated pharmacokinetics and pharmacodynamics in drug development

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

Suchergebnisse filtern